BUDGET IMPACT ANALYSIS OF INTRODUCTION OF RITUXIMAB BIOSIMILAR IN THE UNITED STATES FROM A PAYER PERSPECTIVE

被引：0
|
作者：
Ektare, V [1 ]
Liu, R. [2 ]
Stephens, J. [2 ]
Al Taie, A. [3 ]
Shelbaya, A. [3 ,4 ]
机构：
[1] Pharmerit India Private Ltd, Mumbai, Maharashtra, India
[2] Pharmerit Int, Bethesda, MD USA
[3] Pfizer Inc, New York, NY USA
[4] Columbia Univ, Mailman Sch Publ Hlth, New York, NY 10027 USA
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PBI17
引用
收藏
页码：S16 / S17
页数：2
相关论文
共 50 条
  • [31] Impact of changes in reimbursement system on the budget from the payer's and patient's perspective
    Skowron, A.
    VALUE IN HEALTH, 2007, 10 (06) : A409 - A410
  • [32] Budget Impact Analysis of Biosimilar Natalizumab in the US
    Li, Edward
    Goh, Adrian
    Gupta, Soni
    Schauf, Marion
    Chen, Anna
    Hartung, Daniel M.
    AMERICAN JOURNAL OF MANAGED CARE, 2024, 30 (06): : e191 - e197
  • [33] Budget impact analysis of introducing fruquintinib for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy and biologics in the United States from the payer perspective
    Paly, Victoria Federico
    Li, Shujun
    Khanduri, Pratishtha
    Asfaw, Alemseged Ayele
    Zou, Denise
    Hernandez, Luis
    JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 1076 - 1085
  • [34] BUDGET IMPACT ANALYSIS OF ECULIZUMAB BIOSIMILAR FOR TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA FROM PUBLIC HOSPITAL PERSPECTIVE IN 2023
    Robin, P.
    De Coucy, A.
    Hadjadj, C.
    Petiteau, Moreau F.
    VALUE IN HEALTH, 2024, 27 (06) : S10 - S10
  • [35] THE ECONOMIC IMPACT OF SWITCHING TO TRASTUZUMAB BIOSIMILAR FOR THE TREATMENT OF METASTATIC BREAST CANCER FROM A CHINESE PAYER PERSPECTIVE
    Liu, S.
    Bozkaya, D.
    Brown, D.
    VALUE IN HEALTH, 2018, 21 : S2 - S2
  • [36] BUDGET IMPACT MODEL OF HEMOPHILIA A TREATMENT IN TURKEY: A PAYER'S PERSPECTIVE
    Kayadibinli, M.
    Ulus, P.
    Durguner, B.
    VALUE IN HEALTH, 2011, 14 (07) : A412 - A412
  • [37] BUDGET IMPACT ANALYSIS OF LAROTRECTINIB FOR 8 TUMORS IN THE UNITED STATES
    Hansen, R.
    Williamson, T.
    Cameron, J.
    Suh, K.
    Carlson, J.
    Sullivan, S. D.
    VALUE IN HEALTH, 2019, 22 : S76 - S76
  • [38] BUDGET IMPACT ANALYSIS OF THE INTRODUCTION OF DEXCOM ONE FOR THE TREATMENT OF PATIENTS WITH T2 DIABETES ON AN INTENSIVE INSULIN SCHEDULE FROM THE PERSPECTIVE OF THE ITALIAN HEALTHCARE PAYER
    Genugten, M.
    Grifi, M.
    VALUE IN HEALTH, 2023, 26 (12) : S53 - S53
  • [39] BUDGET IMPACT ANALYSIS OF ENZALUTAMIDE FOR TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER FROM A US PAYER PERSPECTIVE
    Bui, C. N.
    O'Day, K.
    Flanders, S.
    Oestreicher, N.
    Francis, P.
    Posta, L.
    Popelar, B.
    Tang, H.
    Balk, M.
    VALUE IN HEALTH, 2015, 18 (03) : A196 - A196
  • [40] Assessing health plan payer's budget impact of etranacogene dezaparvovec for the treatment of hemophilia B in the United States
    Wilson, Michele
    McDade, Cheryl
    Thiruvillakkat, Kris
    Rouse, Robert
    Sivamurthy, Krupa
    Yan, Songkai
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2024, 30 (08): : 805 - 816
12345